IMAX China Holding (NYSE: IMAX) reported full-year 2020 increase in revenue

Credit Twitter


IMAX China Holding, Inc. (NYSE: IMAX) today reported full-year 2020 results highlighted by second-half box office which returned to 80% of the prior year period on an average daily basis, and continued network growth as theatres reopened in late July. Greater China revenue for the full-year 2020 was approximately US$52.3 million, down 58% year-over-year, and adjusted net loss of approximately US$4.6 million, due to COVID-related theatre closures from late January to late July. Total revenue of approximately US$45.6 million and a profitability turnaround to approximately US$10.9 million adjusted earnings for the second-half of 2020 reflects a strong rebound in box office despite the temporary delayed release of major Hollywood tentpole films, as well as increased installation activities.


 IMAX Logo. (PRNewsFoto/IMAX Corporation)  


“We are pleased to see an impressive resurgence in box office upon theatre reopenings as Chinese audiences come back to IMAX – more than ever – underscoring the growing demand for blockbusters and the strength of our brand as the pinnacle of a premium out of home entertainment experience,” said Richard L. Gelfond, Chairman of IMAX China. “Despite the unprecedented challenges in 2020, we hit new records in multiple key theatrical windows, including National Holiday, New Year’s Day and Chinese New Year, highlighted by our meaningful market share gains in local language titles as productions increasingly lend themselves to IMAX. Our continued signings momentum with leading exhibitors, including Wanda and Jinyi, and our backlog of 251 theaters illustrates our partners’ long-term commitment to the IMAX Experience.”

“IMAX China’s premium positioning built upon our brand, technology and network scalability has only been further strengthened post-pandemic as theatrical entertainment increasingly calls upon differentiated offerings in both content and exhibition,” said Mr. Gelfond. “Given the recent recovery in our business, strong cash position and the recurring cash flow generating ability of our network, we are happy to announce we maintained a stable annual dividend per share in 2020 as in prior years and will increase our future dividend payout ratio from 33% to 50% of net income, despite the earnings impact from COVID-19 in 2020.”

“Despite a six-month theatre closure and the temporary delay of major Hollywood tentpoles, IMAX China delivered box office share gains with local language blockbusters, continued network growth and expansion in new theatre signings– a strong testament to IMAX China’s commercial value to consumers, filmmakers and exhibition partners,” said Edwin Tan, Chief Executive Officer of IMAX China. “We feel very well-positioned to continue delivering above-industry growth on our strengthening footprint in local language films and a film slate increasingly empowered with IMAX DNA”

IMAX China Dividend

IMAX China today announced that its Board of Directors recommended the payment of a final dividend of US$0.02 per share or approximately US$7 million in total, based on the total number of shares in issue as of 31/12/2020. The dividend will need to be voted on by the shareholders at the Company’s annual general meeting. IMAX China also announced a dividend payout ratio of 50% of net income from 2021 onwards, up from the 33% it had paid out during the pre-COVID years of 2017 to 2019.

Recent Developments

In February 2021, to maximize liquidity, the Company sold all of its 7,949,000 shares of Maoyan for total gross proceeds of US$17.8 million.

Network Update

Despite COVID-19 related theatre closures through late July, the Company delivered further network expansion with a total of 745 systems in the IMAX® theatre network in Greater China as of December 31, 2020. The Company signed agreements for 38 theater systems in full year 2020, bringing total backlog to 251 theater systems as of December 31, 2020. Signings were headlined by a 20-theatre agreement with Wanda, the largest exhibitor in China, and a 12-theatre deal with Jinyi, the second-largest exhibition partner of IMAX China. Both agreements involve upgrades of top performing theaters to IMAX with Laser® projection systems and the addition of new IMAX locations across the country.

The Company installed 42 new and upgraded theatre systems during the full-year 2020, compared to 95 installations in 2019. The year-over-year decline is due to suspended development activities through a portion of the third quarter as a result of COVID-19. Among the 745 systems in Greater China as of December 31, 2020, 376 operate under full revenue sharing arrangements, 106 under hybrid revenue sharing arrangements and 263 operate under sales arrangements.

Box Office Update

The Company’s refined local language programming strategy, expanding network and growing consumer recognition as the ‘go-to’ destination for blockbusters drove a strong rebound of IMAX China’s gross box office to approximately US$92 million since theatres reopened in mainland China late July through end of 2020. This represents an approximately 3.6% box office market share, up from 2.8% in the prior year period. In 2020, the top five grossing titles accounted for 47% of industry box office in mainland China, all of which were available in the IMAX theatre network.

Greater China Key Metrics

Twelve months ended December 31,
2020 2019
Greater China Signings
Sales 20 20
Revenue Share 1 43
IMAX with Laser Upgrade 17 1
Total 38 64
Greater China Theatre Installations
Sales 15 27
Revenue Share 21 56
IMAX with Laser Upgrade 3 12
Relocation 3 0
Total 42 95
Greater China Network
Commercial Multiplex 729 702
Institutional 16 15
Total 745 717
Greater China Backlog 251 253
IMAX Greater China Box Office US$99 million US$366 million
Film Count
Mainland China 25 44
HK/ Taiwan Only 8 7
Total 33 51

Follow us on Google news for more updates and News


This content is being provided to you for informational purposes only. The content has been prepared by third parties not affiliated with CWEB Inc, a business. This content and any information contained therein, does not constitute a recommendation by CWEB to buy, sell or hold any security, financial product or instrument referenced in the content. This information neither is, nor should be construed as an offer, or a solicitation of an offer, to buy or sell securities by CWEB Inc. CWEB Inc. does not offer or provide any opinion regarding the nature, potential, value, suitability or profitability of any particular investment or investment strategy, and you shall be fully responsible for any investment decisions you make, and such decisions will be based solely on your evaluation of your financial circumstances, investment objectives, risk tolerance, and liquidity needs.

Unless stated otherwise, the web content provided by the CWEB family of companies is for educational purposes only. The information and tools provided neither are, nor should be construed, as an offer, or a solicitation of an offer, to buy or sell securities by CWEB Inc. or its affiliates. Unless stated otherwise, no information presented constitutes a recommendation by CWEB Inc. or its affiliates to buy, sell or hold any security, financial product or instrument discussed therein or to engage in any specific investment strategy.

Full Disclaimer

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.